PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission.
Mathieu N, Hupé M, Heluwaert F, Rivière P, Hébuterne X, Chupin A, Abitbol V, Bouguen G, Vuitton L, Gornet JM, Montuclard C, Nancey S, Cadiot G, Wils P, Gilletta C, de Maissin A, Altwegg R, Chanteloup E, Plastaras L, Ah Soune P, Bourreille A, Stefanescu C, Seksik P, Simon M, Uzzan M, Andrau P, Rouillon C, Arondel Y, Buisson A, Peyrin-Biroulet L, Mboup B, Vicaut E, Laharie D.
Mathieu N, et al.
Clin Gastroenterol Hepatol. 2025 Dec;23(13):2597-2606. doi: 10.1016/j.cgh.2025.04.028. Epub 2025 May 19.
Clin Gastroenterol Hepatol. 2025.
PMID: 40398832